Nope. Moderna's share price and general outlook has flatlined at its pre-2020 levels a long time ago. They have no products, they aren't well capitalized and they might liquidate at some point. This vaccine was a no-hoper like all other Moderna's products. That's why the article says: "Shares of Moderna were flat in after-market trading." The smart money wasn't surprised because this was never going to make it to market.

Although this will be interpreted on the left as a partisan move (with the administration lying under duress or something), it's likely that they're telling the truth about why it was cancelled. Trump after all was a big supporter of the Moderna vaccines. But mRNA tech just doesn't work when normal safety standards are re-imposed. I wrote about the problem here a couple of weeks ago:

https://news.ycombinator.com/item?id=44003338

It's easy to forget that the COVID vaccines were an emergency measure. The way they were judged wasn't how pharma products are normally judged.